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The medical treatment of patients with chronic primary headache syndromes (chronic migraine, chronic tension-type
headache, chronic cluster headache, hemicrania continua) is challenging as serious side effects frequently complicate
the course of medical treatment and some patients may be even medically intractable. When a definitive lack of
responsiveness to conservative treatments is ascertained and medication overuse headache is excluded,
neuromodulation options can be considered in selected cases.
Here, the various invasive and non-invasive approaches, such as hypothalamic deep brain stimulation, occipital nerve
stimulation, stimulation of sphenopalatine ganglion, cervical spinal cord stimulation, vagus nerve stimulation,
transcranial direct current stimulation, repetitive transcranial magnetic stimulation, and transcutaneous electrical nerve
stimulation are extensively published although proper RCT-based evidence is limited. The European Headache
Federation herewith provides a consensus statement on the clinical use of neuromodulation in headache, based on
theoretical background, clinical data, and side effect of each method. This international consensus further gives
recommendations for future studies on these new approaches.
In spite of a growing field of stimulation devices in headaches treatment, further controlled studies to validate,
strengthen and disseminate the use of neurostimulation are clearly warranted. Consequently, until these data are
available any neurostimulation device should only be used in patients with medically intractable syndromes from
tertiary headache centers either as part of a valid study or have shown to be effective in such controlled studies with
an acceptable side effect profile.
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Although headache is a common disease, its more severe
manifestations such as intractable migraine and trigemi-
nal autonomic cephalalgias have a debilitating effect on
patients resulting in chronic pain and severe functional
impairment. The recent Global Burden of Disease Study
2010 (GBD2010), conducted by the World Health
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in any medium, provided the original work is pestimates a worldwide prevalence of migraine of 14.7%,
ranking it third place among the most common diseases
and at the seventh place among specific causes of dis-
ability and top of all neurological disorders as cause of
total years lived with disability [1,2].
Although excellent international guidelines for organ-
isation of headache service and management have been
introduced [3-5] there is no single standard of care for
patients presenting with primary chronic headache
symptoms. For example, treatment choices for acute
migraine are based on headache severity, attack
frequency, associated symptoms, and co-morbidities.
Despite significant improvement in management ofis an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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still a challenge because of inadequate response of medi-
cations and difficulty in predicting individual response
to a specific agent or dose.
The medical treatment of patients with chronic pri-
mary headache syndromes (such as chronic migraine,
chronic cluster headache, chronic tension-type headache
or hemicrania continua) is particularly challenging as
valid studies are few and in many cases even higher
doses of preventative medication is ineffective and ad-
verse side effects frequently complicate the course of
medical treatment.
Chronic headaches that do not or no longer respond to
prophylaxis are commonly encountered at tertiary level
headache centres [6]. The vast majority of these patients
suffer from medication overuse headache which can and
should be alleviated by detoxification, but a subset remains
as refractory chronic migraine (RCM) [6]. Although much
work has been accomplished, the definition of RCM is still
a continuous work in progress [7,8]. Cluster headache as
such can also be hard to treat but it may become impos-
sible in chronic cluster headache (CCH) sufferers [9].
Some patients may be intractable to the therapies
recommended by national guidelines, and following the
need of clinicians the word “intractable” has been defined
by Goadsby et al. entitled “Towards a Definition of Intract-
able Headache for Use in Clinical Practice and Trials”
[10]. In these patients, i.e. when the intolerance or lack of
responsiveness to conservative treatments is ascertained,
surgical options are considered. The options has previ-
ously ranged from application of glycerol or local anaes-
thetics into the cisterna trigeminalis of the Gasserian
ganglion; radiofrequency rhizotomy of the Gasserian
ganglion or of the trigeminal nerve; microvascular decom-
pression; resection or blockade of the N. petrosus
superficialis or of the ganglion sphenopalatinum and to a
whole range of other ablative or destructive methods. Case
reports of the complete inefficacy of surgical treatment, at
least in cluster headache and related syndromes exists
[11-14]. It follows that surgical procedures should be
considered with great caution because no reliable long
term observational data are available and because they can
induce a secondary chronic pain condition as trigeminal
neuralgia and/or anaesthesia dolorosa. Technical progress
has recently introduced the opportunity to use neuro-
stimulation rather than ablative or destructive methods
and it may be applied to virtually any neural structure, in-
cluding spinal cord, deep brain structures, motor cortex
and peripheral nerves. It is not known how electrical
stimulation of central or peripheral target structures exerts
its effects, although a neuronal functional block seems the
most likely option.
Almost all the mentioned therapies for RCM and CCH
require weeks to months of stimulation for a prophy-lactic effect to occur, suggesting neuronal plasticity as a
possible mechanism, and only stimulation of the spheno-
palatine ganglion in CCH has demonstrated an acute,
abortive effect [15]. Predictors of effectiveness for all
modes of neurostimulation still need to be identified and
in the future, the least invasive and most effective strat-
egy must be preferred as first-line therapy for intractable
chronic headaches [16].
Likewise neurostimulation should only be considered
in patients that have tried all first-line therapies
recommended in European guidelines [3], and that clini-
cians need to follow international consensus on that
matter [10,17].
The neuroanatomical targets for these techniques vary.
The theoretical mechanisms, therefore, may vary depend-
ing on the location of stimulation. Invasive neuromo-
dulatory procedures comprise stimulation of the central
nervous system (hypothalamic deep brain stimulation
(hDBS)) and spinal cord stimulation (SCS) and of the
peripheral nerves (occipital nerve stimulation (ONS),
sphenopalatine ganglion stimulation (SPG). Non-invasive
variants comprise vagus nerve stimulation (VNS), transcu-
taneous electrical nerve stimulation (TENS), repetitive
transcranial magnetic stimulation (rTMS) and transcranial
direct current stimulation (tDCS).
We aim to provide expert recommendations on the
basis of a detailed review the present literature, a sum-
mary of clinical expertise and present a position for
standard of care in the use of neuromodulation in
chronic primary headaches in Europe.
Methods
This review represents the view of the European
Headache Federation (EHF) on this topic. The mem-
bers of the Expert Group on Neuromodulation of
chronic headache were appointed on the basis of their
specific expertise on the topic with the necessary
multidisciplinary approach.
All currently existing methods of neuromodulation
have been reviewed and analysed if at least two case
series have been published and the indications and limits
of each of these methods are presented. Details of the
ethical considerations and various study approvals are
provided in the background literature, please see the ref-
erence list. Because the field is fast evolving and because
neurostimulation has the intrinsic and principal chal-
lenge of unavailable placebo or sham conditions, this
recommendation cannot strictly follow evidence based
methods approaches. However, a modified Delphi con-
ference mainly using Internet facilities has been used
and all participants agreed to the recommendations
presented here. This paper is therefore not a conven-
tional guideline but international expert recommenda-
tions strictly based on published evidence.
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Hypothalamic stimulation
Theoretical background
Hypothalamic stimulation for drug-refractory CCH became
a therapeutical target after PET studies showed increased
blood flow in the posterior hypothalamus during cluster
headache attacks [18], which was interpreted as neuronal
activation of that brain area. A year later structural changes
in the same brain area was demonstrated [19].
Clinical data
In 2000, soon after these seminal studies, the first
hypothalamic implantation and stimulation for drug-
refractory CCH (dCCH) was performed [20] with favou-
rable results. So far, data on more than 60 hypothalamic
implanted patients are archived in the literature and
include cluster headache patients and other types of tri-
geminal autonomic cephalalgia [20-39]. The overall suc-
cess rate (patients pain-free or with ≥50% improvement)
is around 50-60% and accumulated follow-up has made
it possible to better understand advantages and limita-
tions of the procedure.
The largest series to date comprises 19 severe dCCH
patients [33]: after a mean follow-up of 8.7 years, long-
lasting improvement was present in 71% (12/17) with 6
persistently almost pain free and another 6 no longer ex-
periencing daily attacks but episodic attacks interspersed
with long-lasting remission [33]. The pain free state was
maintained after the stimulators had been off for a me-
dian of 3 years (range 3–4) in 5 patients, but this only
happened after several years of continuous stimulation
[33]. Most patients have headache recurrence a short
time after the stimulator is switched off, or the battery
runs out [20-39]. Five patients did not have benefit; 4 of
these had bilateral cluster headache. Three of the non-
responders experienced relief for the first 1–2 years but
then developed tolerance [33]. Adverse events were elec-
trode displacement (N=2), infection (electrode N=3; gen-
erator N=1), electrode mal-positioning (N=1), transient
non-symptomatic 3rd ventricle haemorrhage (N=1), per-
sistent slight muscle weakness on one side (N=1), and a
seizure (N=1) [33]. Smaller studies have reported similar
efficacy [20-39].
Eleven drug-resistant CCH patients were randomized
to effective vs. sham posterior hypothalamic stimulation.
No difference was detected between the two arms after
one month, probably in relation to the short duration of
treatment [30]. In the subsequent open-label phase, all
patients received openly verum stimulation and three
patients became pain free, and three others had a ≥50%
reduction in attack frequency after 10 months.
Posterior hypothalamic activation has also been shown
to be effective in three patients with short-lasting
neuralgiform headache attacks with conjunctival injec-tion and tearing (SUNCT), a rare form of trigeminal
autonomic cephalgia. [40-42] The first patient became
pain-free but additional prophylaxis with lamotrigine
was necessary [40]. Another patient had a clinically sig-
nificant reduction in attack frequency (from 120 to 25/
day after a year) [41]. In the third patient [42] attack
frequency dropped from 30/day to sporadic attacks after
15 months of continuous stimulation. A patient with
chronic paroxysmal hemicrania also obtained relief after
posterior hypothalamic stimulation [43].
Posterior hypothalamic stimulation has also been tested
to abort acute cluster headache attacks. Treatment
consisted of switching the stimulator on or increasing
stimulation intensity. One hundred eight attacks were as-
sessable and a ≥50% reduction in pain intensity was
reported only in 23%; it was concluded that DBS is not
useful for acute treatment of cluster headache [39].
Safety and adverse effects
Overall, posterior hypothalamic stimulation is well toler-
ated years after implantation, but is not without risk:
one patient died of intracerebral haemorrhage [21] and
another had a subclinical 3rd ventricle haemorrhage
[22]. In movement disorders, deep brain stimulation
carries about a 3% risk of brain haemorrhage [40]. To
reduce this risk Seijo et al. slightly shifted the hypothal-
amic target laterally so that the electrode tip was further
from the lateral ventricle wall, without changing efficacy
[32]. In line with this observation, a neuroimaging study
showed that the anatomical location of the stimulating
electrodes did not differ significantly between responders
and non-responders [41]. Panic attacks [22], oculomotor
disturbances, intraoperative transient ischaemic attack,
subcutaneous infection, transient loss of consciousness
with hemiparesis and micturition syncope, erectile dys-
function, and paroxysmal sneezing [20-33,42] have also
been reported. Heart rate, blood pressure, and respira-
tory rate are not affected by hypothalamic stimulation
when amplitude is increased slowly; however, sudden in-
crease in amplitude can provoke autonomic and oculo-
motor disturbances [43]. Quality of sleep is improved
during hypothalamic stimulation, possibly because of the
suppression of nocturnal cluster headache attacks [44].
Technical considerations
The first attempt to treat CCH by neuromodulation pro-
cedures was based on neuroimaging and particularly on
the observation that a discrete volume of the posterior
hypothalamus was activated during the pain bouts in
CCH patients. The target of the procedure was the al-
leged hyperactive posterior hypothalamus (pHyp) and its
inhibition was obtained delivering “in situ” high fre-
quency current (180 Hz, 1–3 V, 60–90 μs pulse width)
trough deep implanted electrodes.
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DBS is an invasive, expensive and probably non-specific
technique that must be employed with caution and only
carefully considered for the most severely affected pa-
tients with medically refractive CCH when other less in-
vasive strategies have been employed. The hypothesis
leading to the introduction of hypothalamic stimulation
as a treatment for CCH was that high frequency elec-
trode stimulation could reduce hypothalamic activation
during a headache attack [12]. After long-term experi-
ence with the technique, it is now evident that this
hypothesis is not correct: in fact acute hypothalamic
stimulation does not abort acute cluster headache at-
tacks [33], and it takes time – latency – for a prophylac-
tic effect to develop, comparable to the delay in dystonia
[20-33]. Taken together these observations indicate that
stimulation works by a more complex mechanism, pos-
sibly brain plasticity [33,45-48].
Occipital nerve stimulation (ONS)
Theoretical background
The rationale for the use of occipital nerve stimulation
(ONS) in headaches came from animal studies showing
the convergence of cervical, somatic and dural afferents
on second order nociceptors in the trigeminocervical
complex [49,50]. That suboccipital steroid injections
turned out to be effective in the prevention of several
primary headaches [51-53] was in favour of the existence
of these anatomical connexions in humans. More than a
decade ago, Weiner and Reed had already treated pa-
tients suffering from “occipital neuralgia” with ONS
[54]. Their work paved the way for the use of this less
invasive method of neurostimulation in various chronic
headache types, essentially CCH and CM.
Clinical data
Up to now 3 randomized sham-controlled (RCTs) ONS
trials have been performed in CM [55-57] and their out-
come is overall disappointing. The evaluation period was
set at 12 weeks of ONS treatment in all of them. In the
PRISM trial [55], available in abstract form only, 125
drug-refractory CM patients were treated with ONS or
sham without any significant improvement. In the
ONSTIM trial [56], 39% of patients (N=66) treated with
active ONS during 3 months had at least 50% reduction
in headache frequency and/or a 3-point intensity scale
decrease, while there was no improvement in the non-
stimulated or ineffectively stimulated groups. Finally, in
a recent trial on 157 patients [57], the percentage of re-
sponders did not differ between active (17.1%) and con-
trol (13.5%) groups (primary endpoint). However, the
number of headache days was significantly reduced in
the ONS group compared to the sham population
(−27.2% vs. -14.9%). The migraine-related disability alsodecreased with ONS. The main issue of this study is that
patients were definitely not blinded to ONS (see below).
Other existing studies of ONS in CM are small open tri-
als or case reports (see [58] for review). Interestingly, the
combination of occipital and supraorbital neurostimu-
lation in an uncontrolled series of 7 CM patients [59]
produced a ≥90% headache frequency improvement in
all patients, while there was no significant response to
either stimulation alone.
ONS has also been used in dCCH, but only open stud-
ies have been performed and in smaller groups of pa-
tients compared to the CM series. In the 3 main trials
(13–15 patients), the success rate was slightly superior
to 60% [58]. Burns et al. reported that after an average
of 17.5 months under ONS therapy, 10/14 CCH patients
were clinically improved: 3 had an improvement ≥90%,
3 a moderate amelioration (40-60%) and 4 a mild im-
provement (20-30%) [60]. In another study, 15 drCCH
patients were prospectively followed up to 5 years after
ONS implantation (mean 36.8 months) [61,62]. One pa-
tient was not evaluable due to an immediate device in-
fection. Among the 14 remaining patients nearly 80%
had a ≥90% reduction in attack frequency and 60%
remained pain-free during long time periods (months to
years). In another recent prospective trial (N=13, [63])
attack frequency decreased on average by 68% and in-
tensity improved by 49%. Eight out of 13 patients were
able to reduce or stop their preventive medications.
Other smaller studies also report beneficial outcome of
CCH patients under ONS (see [58] for review).
As far as other chronic forms of primary headaches
are concerned, Burns et al. performed ONS in 6 patients
with hemicrania continua (6–21 months [64]), and
reported that 4 of them had a pain reduction exceeding
80%. Nine patients with drug-resistant SUNCT and 3
with SUNA (short-lasting unilateral neuralgiform head-
ache attacks with conjunctival injection and tearing –
SUNCT- or with autonomic symptoms - SUNA) had a
benefit of at least 50% under ONS and 4 patients were
nearly pain free after +/− 14 months follow-up [65,66].
Safety and adverse effects
ONS is relatively safe compared to other invasive tech-
niques, chiefly hypothalamic deep brain stimulation. The
most frequent adverse events are lead migration, local
immediate or delayed infections and battery depletion
due to high stimulation intensities needed to obtain an
optimal nerve stimulation in some patients (64% in
[61]). Patients also complain of unpleasant traction on
the connecting cables and sometimes do not tolerate the
paraesthesias induced by the stimulation of the occipital
nerves. Patients received generally bilateral ONS im-
plantation even in side-locked headache forms, and in
the only unilateral ONS series (in CCH) a headache
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ONS is therefore recommended.
ONS induces paraesthesias, like every other peripheral
nerve stimulation. In our experience, the feeling of par-
aesthesias (covering the great occipital nerve or GON
territory) appears mandatory to obtain a clinical im-
provement in CCH patients treated with ONS [61], but
this is not always the case. Patients who do not feel the
paraesthesias anymore (because of lead migration or bat-
tery depletion) often describe a recurrence of their head-
ache attacks within the following days. There are no
data demonstrating that ONS efficacy is conditioned by
the stimulation of the GON or of the lesser occipital
nerve or both, or correlated to the size of the area cov-
ered by paraesthesias. This phenomenon points out the
main issue of ONS RCTs in headaches, i.e. the blinding.
In CCH all available ONS studies are open trials and a
placebo effect cannot be ruled out, even if in most pa-
tients attacks quickly relapsed after the stimulator was
switched off. In CM more valid data are available and
the outcome of the above mentioned RCTs is rather dis-
appointing. More studies predicting a possible effect of
ONS and patient selection are clearly warranted.
Few studies have been performed to understand ONS
mechanisms in chronic headaches, and they suggested
that ONS had a nonspecific neuromodulatory effect on
central pain control systems. Hence, 36% of CCH pa-
tients successfully treated with ONS had still autonomic
attacks despite the disappearance of the pain itself [61].
An 18FDG positron emission tomography (PET) study
in 10 ONS-treated CCH patients showed an ipsilateral
hypothalamic hyperactivity that remained unchanged
during ONS therapy, contrary to the activity in pain
transmitting cortical networks which normalized under
ONS [66,67]. Similar modifications were also reported
with activation PET in CM patients treated with ONS
[68]. One could speculate that the ONS stimulation has
an effect on the peripheral pain transmission but not on
the central modulating areas.
Technical considerations
There are many different stimulation electrodes but no
comparative studies. The electrodes have to cross the
GON in its subcutaneous course. Despite a great inter-
individual anatomical variability, the GON becomes
superficial approximately 1 cm below the occiput and
2–4 cm from the midline [69]. Consequently electrodes
should ideally cover this spot. The electrodes have to be
implanted subcutaneously above the fascia and always
above the GON, which exhibit great anatomical variabil-
ity [69]. As electrode migration is the most frequent
complication, the leads have to be anchored firmly to
the epifascial plane. Performing loops with the leads is
recommended to allow extension of the leads duringmovements. Bilateral stimulation is recommended to
avoid headache side-shift [61,62]. Implantation of the
generator in the buttock is not recommended because
the risk of migration could be higher. The release of
flexible cables, epifascial anchoring and rechargeable
batteries should decrease the cervical discomfort, lead
migrations and battery depletion problems [58].
Limitations and recommendation for future studies
ONS is an invasive, expensive and probably non-specific
technique that must be employed with caution and only
carefully considered for the most severely affected patients
with medically refractive CCH. ONS demonstrated only
preventive but no acute effect, with the exception of some
chronic migraine patients [68]. Upcoming studies should
be prospective, introduce a proper control and take the
technical ONS challenges such as lead migration, frequent
infections and proper blinding procedures into account.
The mode of action is still speculative and the scientific
evidence for a long lasting efficacy is lacking [70].
Stimulation of the sphenopalatine ganglion (SPG)
Theoretical background
Strictly half-sided trigeminal pain along with parasympa-
thetic activation is a central diagnostic feature of all
trigeminal autonomic cephalgias (TAC’s) [71]. Conse-
quently, several studies have targeted the facial parasym-
pathetic output by blocking [72,73] or lesioning [74] the
sphenopalatine ganglion (SPG). The SPG is a large
extracranial parasympathetic ganglion located in the
pterygopalatine fossa (PPF). Post-ganglionic parasympa-
thetic fibers from the SPG innervate facial structures
such as the salivary and lacrimal glands, the nasopharyn-
geal mucosa and the cerebral and meningeal blood ves-
sels [75]. Because cluster headache is such a vicious pain
which is not always medically treatable [9], various inva-
sive interventions in the PPF have been tried including
alcohol injection, thermocoagulation [76], transnasal
injection of lidocaine [73], neuroablation [77], radio-
frequency lesions [78] and pulsed radiofrequency abla-
tions [74]. The success rates seem promising (varying
from 46 to 85%), but the benefits have been transient
[79]. Because of this transient nature and because of the
irreparable side effects of the lesioning interventions, a
non-destructive approach using acute percutaneous
SPGS with a removable electrode was examined in five
patients with cluster headache. This small pilot study
showed a success rate of 61% [80], which led to another
pilot study in patients with acute migraine attacks which
also showed some efficacy [81].
Clinical data
Based on these findings, a new kind of implantable
microstimulator in the facial region was developed and a
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led trial has been conducted to examine the efficacy of
acute stimulation in refractory CCH. This device is
powered and controlled transcutaneously by electromag-
netic waves [15]. In this study, 68% of the 32 enrolled
CCH patients benefited from electrical stimulation of
the SPG [15]. Surprisingly, patients showed two positive
effects: full stimulation of the SPG versus sham stimula-
tion resulted in a significant pain relief (which was the
main outcome parameter) and a significant reduction in
attack frequency. The pain relief and pain freedom rates
at 15 minutes were 67% and 34% respectively and sig-
nificantly greater than with subthreshold or placebo
stimulation. It needs to be pointed out that this study
cannot answer the question how long these effects will
continue but the impression at the moment is that these
effects last and long term follow up studies are under-
way. The surprising observation that there was a signifi-
cant reduction of headache attack frequency in addition
to the acute response has to be seen with caution, as this
study was designed and powered to test the acute effects
on spontaneous cluster headache attacks. Overall, 43%
of patients experienced an attack frequency reduction of
≥ 50% from baseline, which is remarkable as all patients
had been suffering from the CCH for many years and
had tried a number of preventive drugs without benefit.
Given the slight tingling sensation that is accompanying
stimulation of the SPG, a placebo effect cannot be ex-
cluded but the apparent preventive effects of SPG stimu-
lation certainly warrant further investigation.
Safety and adverse effects
Of note, oral maxillofacial surgeries are inherently asso-
ciated with standard peri-operative adverse events, in-
cluding pain, swelling, hematoma, infections and sensory
disturbances. While the rate of device-related complica-
tions was however quite low, sensory disturbance (81%
of patients) and pain (38%) were the most frequent side-
effects immediately after the implantation, mainly affect-
ing maxillary nerve branches. However, after 3 months,
only 16% of patients suffered from ongoing and mild
sensory disturbance and 19% from local pain, respect-
ively [20]. No other significant neurological side effects
were observed. In summary, local sensory impairment
seems to be a mild complication compared to the severe
cluster attacks but the implantation procedure needs
further attention. Overall, SPG stimulation appears to
rank among the minimally invasive and safe neuromo-
dulatory strategies.
Technical considerations
Implantation of the ATI-SPG-Stimulator is done under
general anesthesia via a vestibular incision of the poster-
ior maxillary mucosa of the affected side (trans-oral,gingival buccal technique). The stimulating electrodes
on the integral lead are positioned within the PPF prox-
imate to the SPG, with the body of the SPG Neuro-
stimulator positioned on the lateral-posterior maxilla
medial to the zygoma and anchored to the zygomatic
process of the maxilla using the integral fixation plate.
After implantation, positioning control is confirmed by
doing a three-dimensional imaging (parasinus CT) of
the PPF. Patients then undergo a therapy titration period
during which stimulation parameters are to be adjusted
bi-weekly. Individual electrical stimulation parameters
are adjusted according to provoked paresthesias in the
root of the nose and/or treatment effect during an at-
tack. The maximum amplitude is usually programmed
to be slightly higher than the amplitude that provoked
discomfort in each patient. If neurostimulator lead posi-
tioning is determined to be incorrect, a lead revision
procedure should be considered.
Limitations and recommendation for future studies
Judging from the published data, the input of the para-
sympathetic system in the origination of cluster head-
ache attacks is significant. This is underlined by a recent
report that low-frequency SPG stimulation can provoke
attacks in patients with cluster headache which in turn
can be treated with high-frequency stimulation [82]. It
has to be kept in mind that all of the above data have
been reported in medically intractable patients with
CCH. It may be worthwhile using the method of SPG
stimulation in episodic cluster headache patients, how-
ever, given the above mentioned side effects, only in pa-
tients with particularly long active bouts and failure of
preventative medication. Given that only one placebo-
controlled study exists to date, this method should be
still seen as experimental until further studies are
presented.
Vagal nerve stimulation (VNS)
Theoretical background
The first investigations on the modulation of nociception
by vagal afferents were performed approximately 20
years ago [83-85]. In animals it has been demonstrated
that electrical, chemical, and physiologic activation of
vagal afferents produces analgesic effect [86-91]. The ac-
tivation of vagal afferents decreases the activity of sec-
ond order nociceptive neurons in the spinothalamic and
spinoreticular tract of the spinal cord [84,88,92] –
resulting in inhibition of spinal nociceptive reflexes and
spinal nociceptive transmission [87,92] – and in the tri-
geminal nuclear complex [93-95].
Clinical data
Only smaller open case series exist. In a retrospective
survey, three of four patients with implanted VNS
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quency and pain scores [96]. One of the 4 patients be-
came migraine-free 1 month after the onset of VNS. A
second patient had a reduction of >50% in both fre-
quency and severity. A third patient reported >50% re-
duction in frequency. The final patient had a slight
reduction in both frequency and severity. Improvement
was reported to start 1 to 3 months after initiation of
therapy. In another retrospective study, eight of ten pa-
tients with migraine had a 50% or more reduction in
headache frequency, with five of them completely head-
ache free in the 6 months after treatment initiation, with
improvement occurring in the first 3 months following
stimulator placement [97].
A case series reported a good response to VNS in two
of four patients with chronic migraine (one with a
subdiagnose of basilar-type migraine (BTM) and hemi-
plegic migraine (HM) and the other with BTM) and in
two patients with CCH [98]. Recently, a novel method
has been described to non-invasively stimulate brain
structures in a similar way to VNS [99-101]. The
method is based on the technique of transcutaneous
electrical nerve stimulation (TENS), which is used in
acute and chronic pain syndromes. t-VNS is delivered by
a medical device to the left auricular branch of the vagus
nerve (t-VNS) located medial of the tragus at the entry
of the acoustic meatus without any surgery. Another
novel method is also thought to stimulate the vagus
nerve transcutaneously (tVNS). Preliminary data sug-
gested that tVNS could be effective in selected patients
[102]. In a pilot trial evaluating 13 primary headache suf-
ferers, however, ten stopped tVNS because lack of effi-
cacy and/or side effects [103].Safety and adverse effects
The very limited experience with both implantable and
transcutaneous VNS prohibits a clear presentation of
safety and limitations in use. Based on the experience of
VNS in medically intractable epilepsy the method seems
fairly safe and mainly hampered by infections and bat-
tery problems. The reported adverse effects are mainly
transient muscle cramps and local pain, which can be re-
duced by the applied stimulation paradigm. So far, no
significant safety issues have been raised but clinical ex-
perience is very scarce.Technical considerations
VNS sends electrical signals along the part of the vagus
nerve that runs through the neck. Data suggests that
VNS reduces the amount of glutamate, substance associ-
ated with headache symptoms, in the brain.
The VNS therapy is administered with a hand held
device, placed on the neck, which produces a mildelectrical signal transmitted to the vagus nerve through
the skin.
It is possible to turn up the stimulation strength until
the patient feels a mild sensation underneath the skin.
The duration of each treatment is approximately 2
minutes.
Limitations and recommendation for future studies
Considering the small series of patients studied, no firm
conclusion can be drawn. Until proper evidence is
provided devices claiming to stimulate the vagus nerve
transcutaneously should be preferred to more invasive
techniques. Due to the lack of evidence, VNS should only
be employed in chronic headache sufferers using a ran-
domized, placebo controlled trial design. Currently some
RCTs are ongoing to validate this therapeutic approach to
chronic headaches (NCT01667250, NCT01701245).
Transcranial direct current stimulation (tDCS)
Theoretical background
Recent progress in transcranial neurostimulation tech-
niques has been used to approach the treatment of chronic
therapy resistant headache. In particular transcranial direct
current stimulation (tDCS) applied through the skull has
been shown to directly modulate the excitability of cortical
areas, best investigated for human motor (for a review see:
[104]) and visual (for a review see: [105]) cortices. tDCS in-
duces both acute and persistent neuronal excitability
changes in the cortex, probably by shifting neuronal resting
membrane potential and hereby modulating the spontan-
eous discharge rates of cortical neurons [106-109]. The
after-effects of tDCS are most easily studied at the primary
motor cortex (M1) by measuring the amplitude changes of
the motor evoked potentials (MEP) using transcranial
magnetic stimulation (TMS) [110]. A minimal duration of
3 minutes and at least 0.4 mA stimulation intensity is ne-
cessary to induce cortical excitability changes outlasting
the stimulation duration [110,111]. At rest, cathodal stimu-
lation induces a decrease and anodal stimulation an in-
crease of cortical excitability. The effect of tDCS origins
intracortically; pharmacological studies have shown that
the effects during stimulation are mediated by ion-
channels, in accordance with a primary hyper- or depolar-
izing effect of the stimulation, while after-effects involve
the modulation of N-methyl-D-aspartate- (NMDA) recep-
tor efficacy [112].
Clinical data
Using tDCS as a treatment for chronic headaches only
data on treatment of orofacial pain [113] and migraine
are available. Based on a concept of cortical hyperex-
citability in migraine cathodal tDCS in migraineurs is
expected to normalize the cortical excitability either (i)
by prophylactic treatment in the interictal phase or (ii)
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attack. So far three studies evaluated the effect of re-
peated application of tDCS as a prophylactic treatment.
Antal et al. [114] has investigated cathodal stimulation
of the primary visual cortex (V1). 30 patients were ran-
domly assigned to cathodal or to sham stimulation. 26
patients participated in the final analyses (cathodal: 13,
sham: 13). Compared to the sham group, only the inten-
sity of the pain was significantly reduced after verum
stimulation.
Auvichayapat [115] and coworkers have investigated
42 episodic migraine patients, that were randomized to
receive either active or sham stimulation on a daily basis
for 20 consecutive days. The results showed statistically
significant reduction in attack frequency and abortive
medications at week 4 and 8 after treatment. The pain
intensity was statistically significant reduced at week 4,
8, and 12.
In the third study [116] thirteen patients with CM
were randomized to receive 10 sessions of anodal (n=8)
or sham (n=5) tDCS for 20 minutes over 4 weeks. There
was a significant interaction term for the pain intensity
and for the length of migraine episodes. Post-hoc ana-
lysis showed a significant improvement in the follow-up
period for the active tDCS group only (delayed
response).
Phase III studies are still missing as well as data in the
acute migraine phase or at the beginning of the aura.
Similarly, there are no data available concerning other
type of headaches, such as cluster and tension- type
headache.Safety and adverse effects
Amongst transcranial stimulation device-based interven-
tions, tDCS is generally considered to be easier to blind
than TMS [117]. The type of stimulation cannot be
judged by an outside observer and it is easily applicable.
By far the most widely reported phenomenon associated
with the application of both active and sham tDCS
stimulation is the itching or tingling sensation under the
electrode [108,114,118]. Other, less frequently reported
phenomena associated with the stimulation are burning
sensations, headache, redness of skin, nausea and light
flashes at the beginning and the end of the stimulation
[119]. It was recently reported that cutaneous perception
does not completely disappear in the first phase of the
stimulation as previously reported but never quantita-
tively assessed [119]. Nevertheless, in naive and even in
experienced participants, no significant differences in
the levels of perceived stimulation strength could be ob-
served between sham and verum stimulation, thus the
ramping up – short stimulation (30 sec) – ramping
down method might be a reliable approach to blindingin tDCS research, at least when using stimulation inten-
sity below 1 mA [119].
Technical considerations
Aftereffects of tDCS are NMDA receptor dependent
[112]. Patients on NMDA receptor antagonists, e.g. on
dextromethorphan, an anticoughing drug, might not
benefit from both anodal and cathodal tDCS. Sodium
channel blocking agents such as carbamazepine and cal-
cium channel blocking agents selectively prevent anodal
tDCS aftereffects [120]. Flunarizine as a calcium antag-
onist is used in some countries for migraine prophylaxis.
Also propranolol shortens both cathodal and anodal af-
tereffects [121]. Rarely safety issues play a role [119,122];
e.g. no metal should be implanted in the head. Precautious
exclusion of patients with previous history of brain surgery
is warranted due to higher current density if the electrode
is closer than 2 cm to a skull deficit. Neurological disor-
ders such as stroke or epilepsy, drug/alcohol dependence,
major psychiatric co-morbidities and implanted pace-
maker may be seen as an exclusion criterion. There is
probably no risk for women in child-bearing age without
contraception, women during pregnancy and lactation to
be expected, if both electrodes are fixed at the skull, how-
ever no data exist on that. It would be prudent to exclude
this group from stimulation.
Limitations and recommendation for future studies
Cathodal V1 stimulation pursues the concept of inhib-
ition of a hyperexcitable visual cortex [114] whereas
anodal M1 stimulation pursues the concept of M1 exci-
tation for reduction of pain perception [115,116]. Stimu-
lation protocols will be further optimized in future.
Repeated applications of the stimulation are probably
necessary, testing different intensities and stimulation
paradigms. For practical use and for longer lasting stud-
ies stimulators that can be used at home should be
available.
It appears to be mandatory for controlled studies that
the subjects or patients are asked after the stimulation if
they believe to be in the verum or placebo group. Simi-
larly, it is important to document the expectation of the
patients with regard to the stimulation outcome in order
to be able to better estimate placebo effects. RCT’s on
other chronic primary headaches are also warranted.
Repetitive transcranial magnetic stimulation (rTMS)
Theoretical background
Introduced by Barker et al. [123], transcranial magnetic
stimulation (TMS) is a neurostimulation tool able to
perform painless cerebral stimulation through applica-
tion of magnetic fields on the scalp. The magnetic
current passes through the scalp and generates a perpen-
dicular electrical current that flows tangentially to cortex
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in repeated pulses, rTMS can determine long lasting
plastic effects that remain also after the end of the train
and depend on the stimulation frequency used: frequen-
cies ≤1 Hz (low-frequency rTMS: LF-rTMS) reducing,
while frequencies >1 Hz (high-frequency rTMS: HF-
rTMS) increasing cortical excitability [124,125].
TMS has been employed in two different ways in
migraine, either to treat the single attack or prevent its
occurrence. Different approaches were done, in consid-
eration of mechanisms subtending the occurrence of
migraine and the development into chronic form
[126-130].
Clinical data
Single pulse trans-cranial magnetic stimulation of the
occipital cortex, was employed by a portable apparatus,
to be tested in migraine with aura attacks in a double
blind sham controlled study, involving a total of 164 pa-
tients and showed a significant effect of verum over
sham treatment [131]. Brighina et al. first [132] evalu-
ated the efficacy and tolerability of HF-rTMS over the
left Dorsolateral Prefrontal Cortex (DLPFC), (an area
known for its top-down control on nociceptive transmis-
sion [133]) for preventive treatment in patients affected
by chronic refractory migraine. Patients were randomly
assigned to active, real (6 patients) or placebo sham
(5 patients) rTMS treatment consisting of 12 stimulation
session delivered on alternate days. As compared to
baseline and sham rTMS, active treatment reduced mi-
graine attacks (about 57% less), drug consumption, head-
ache index, and migraine disability scores) in the month
during and following stimulation. Misra et al. [134] used
HF-rTMS of motor cortex (another area able to exert
control on pain mechanisms [135]) for prophylactic
treatment in patients with episodic and chronic mi-
graine; authors explored also the relationship between
migraine pain and β endorphin plasma levels. The re-
sults demonstrated the ability of M1 rTMS to signifi-
cantly reducing headache frequency (about 85% less at
1st week after stimulation), headache severity, functional
disability and analgesic intake.
Safety and side effects
TMS and rTMS are generally well tolerated and safe as
only minor side effects like transient mild headache or
local pain and paresthesias are reported [136]. However,
the procedure is to be avoided in patient with skull de-
fect or with pacemaker, cardiac lines, metal in the head
(electrodes, stimulation devices) or other apparatus that
could be influenced (dislocation, induction of electric
currents) by magnetic field. Caution should be paid in
patient with epilepsy, because a risk (even if really low!)
for seizure is reported. No side effect has been reportedin pregnant women treated with HF-rTMS for refractory
depression, though [137]; however, giving the lack of
enough evidence, rTMS is not recommended in such
condition [137].
Technical considerations
Paradoxical effects to rTMS (facilitation to inhibitory
LF-rTMS or decremental response to facilitatory HF-
rTMS) has been reported in patient with migraine
[138-141]. Moreover, effects of rTMS can be consistently
modulated (influenced) by several drugs (expecially anti-
epileptics like topiramate and valproate) employed in
migraine prophylaxis. These factors should be taken into
account when planning and/or interpreting results of
stimulation trials.
Limitations and recommendation for future studies
Considering the few trials performed and the small
series of patients studied, no firm conclusion can be
drawn by these studies and it is uncertain whether the
effect is acute, preventive or both. rTMS appears to be a
safe [136] and potentially effective tool for treatment of
chronic migraine patients who showed resistance to
pharmacological treatments [58]. Further studies are
needed to assess factors underlying therapeutic effects
(change in cortical excitability, better antinociceptive
control, both?). It’s also to seek for optimal stimulation
parameters (intensity, frequency, number and duration
of stimulation sessions). Another important point may
be the best cortical areas to be modulated for pain con-
trol in migraine, and the most efficacy side of stimula-
tion, though the left side has been more frequently
employed in studies on pain control [142]. Particularly
useful would be the generation of stimulation devices
that patients can use at home.
Transcutaneous stimulation of cranial nerves and TENS
Theoretical background
Transcutaneous electrical stimulation techniques have a
long tradition in chronic pain management. These tech-
niques are rather inexpensive and non-invasive, but the
evidence for their effectiveness is overall of low quality
[143]. There are limited data on the use of electric
current to stimulate cutaneous nerves (transcutaneous
electrical nerve stimulation or TENS) or specific cranial
nerves (supraorbital and supratrochlear) nerve stimula-
tion (tSNS) in the treatment of headache disorders. The
restrictive definition of TENS is the administration by
surface electrodes of electric current produced by a
device to stimulate cutaneous sensory nerves to reduce
pain, both acute and chronic. Indeed, TENS treatment
targets painful regions (or acupoints in electroacu-
puncture) instead of specific nerves. Based on the
stimulation frequency, TENS can be subdivided in low
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quency >10 Hz). As the biological basis of analgesia by
TENS remains speculative, the ‘gate control theory’ of
pain is the most tenable explanation but release of en-
dogenous opiates could be involved [144].
Clinical data TENS and tSNS
TENS
Several meta-analyses on the efficacy of TENS in painful
disorders have yielded ambiguous or negative results
mainly due to inadequate methodology and/or reporting
[143,145-148]. TENS treatment for headache disorders
appeared in the literature as early as 1975 [149]. Acute
effects of TENS have been suggested in a study from
Solomon and Guglielmo published in 1985. Sixty-two
patients with migraine or “muscle contraction head-
ache”, who experienced a headache at the time of their
visit, were divided into 3 different groups receiving
either full high frequency-low intensity TENS, sublim-
inal stimulation or placebo stimulation for 15 min once
resulting in a significant but usually slight to moderate
improvement in pain severity immediately after the
intervention [150]. A Cochrane review from 2004
concluded that the use of TENS for chronic/recurrent
headache (including migraine, tension-type headache,
cervicogenic headache and post-traumatic headache)
prophylaxis is not supported by conclusive evidence
[151], and ever since very little original trial data have
been generated. In a recent trial, the efficacy of intermit-
tent low frequency-high intensity TENS administered to
the temporal and occipital region for a total of 10 weeks
was compared to the preventative effect of 50 mg im-
ipramine per day for 3 months in a sample of 138 pa-
tients with chronic tension-type headache [152]. After 3
months compared to the baseline, the headache intensity
on the VAS score showed a significant decrease in both
approaches with a numerically higher reduction in the
imipramine group. Although the sample size was rela-
tively large, a placebo arm was not included and use of
the VAS score as a primary outcome is questionable.
tSNS
A recent Belgian multi-centric randomized controlled
trial on the efficacy of transcutaneous supraorbital (and
supratrochlear) nerve stimulation (tSNS) in episodic mi-
graine, the PREMICE study, included 67 patients in the
final analysis [153]. A significant decrease of 2.06 head-
ache days per month was observed in the group receiv-
ing full stimulation (p=0.023) compared with only 0.32
days in the sham group (p=0.608) [153]. The comparison
between both groups missed significance by a narrow
margin (p=0.054). The 50% responder rate was signifi-
cantly higher in the verum (38.1%) than in the sham
(12.1%) group (p=0.023). However, the observed effectswere only moderate and despite a number of precau-
tions by the investigators unblinding may have occurred
as effective stimulation induces marked paresthesias
[153]. Therefore, assessment of unblinding should be
mandatory for future neurostimulation studies.
Safety and side effects
High frequency TENS delivered at low intensities is as-
sociated with paraesthesia over the area of stimulation,
and low frequency TENS delivered at high intensities is
associated with a sharp flicking sensation or even muscle
contractions. These sensations hamper proper blinding
in controlled trials.
Technical considerations
Effective blinding with feasible sham paradigms is still
an unresolved issue in transcutaneous stimulation of
cranial nerves and TENS making large-scale studies dif-
ficult. In addition, stimulation parameters differ widely
in TENS studies and consensus settings for clinical stud-
ies are missing.
Limitations and recommendation for future studies
The methodology in headache studies differs profoundly
and a convincing sham paradigm has not been estab-
lished. At present there is insufficient evidence for the
use of TENS in headache prophylaxis and to abort an
acute headache.
Lack of evidence of effect is however different from
evidence of lack of effect [143]. So far, a single study
provided Class III evidence that migraine attacks can be
prevented with tSNS, but the effect size was small,
unblinding may have occurred. The effects of tSNS on
very frequent or chronic migraine are unknown, and re-
fractory patients were excluded. Widespread use outside
of controlled studies of this potentially valuable treat-
ment modality cannot be endorsed at present [153].
Spinal cord stimulation
Theoretical background
The Occipital Nerve Stimulation (ONS) technique takes
advantage of the “functional overlap” of the higher cer-
vical roots and the trigeminal nucleus to neuromodulate,
in a retrograde fashion, the trigemino-cervical complex
[154,155]. However, it is a reasonable assumption that
the application of electrical pulses directly onto the dor-
sal columns at the C2-C3 vertebral level will provide a
neuromodulatory effect on the TCC similar to – if not
greater than – peripheral occipital nerves stimulation.
Cervico-medullary spinal cord stimulation has been used
for the last 30 years to alleviate intractable head and
facial pain [156], but it requires a very costly, time con-
suming and complex neurosurgical procedure and the
mode of action is unknown.
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Performed in few specialised centres and in highly se-
lected patients, and never in a controlled design, it is not
a viable option for primary headaches. Recently, low-
frequency stimulation of the cervical spinal cord (C2-C3
level) has shown positive results in a case series of CCH
patients implanted with a percutaneous cervical epidural
lead [157]. Authors reported a marked reduction in
headache’s frequency (−4.6 attacks per day), intensity
(−2.9 on a VAS score) and duration (−27 minutes per
attack) in 7 patients implanted. The procedure also facil-
itates a 4–19 days testing phase prior to permanent
implant. However, this study was criticized [158].
Safety and adverse effects
Adverse effects such as lead migration, battery depletion
and local infections are inherent in neuromodulatory
approaches and have been reported in hypothalamic
brain stimulation [20-33,42], occipital nerve stimulation
[61,62,68], and stimulation of the sphenoid ganglion
[21]. However, the rate reported in SCS of the cervical
region seems exceedingly high [157,158] and resulted in
repetitive invasive procedures, mostly lead revision.
Given that a dislocation of the lead is an inherent prob-
lem in spinal cord stimulation especially in parts of the
spinal cord with high mobility such as the upper cervical
spine, less invasive methods such as the occipital stimu-
lation or SPG-stimulation should be preferred at least
until ongoing studies (see below) are published.
Technical considerations
Different stimulation frequencies are now available
(burst stimulation, 10 kHz high frequency stimulation)
in SCS. Those provide a new alternative to peripheral
(low-frequency) stimulation due to their ability to
achieve pain relief without causing any perceived sensa-
tion but its efficacy and potential side effects are un-
known. A double-blind, placebo design can now be
considered when planning future randomized control
trials of SCS in chronic, refractory headaches.
Limitations and recommendation for future studies
A “proof of concept” pilot study investigating the initial
tolerability and efficacy of cervical high-frequency SCS
in the treatment of refractory CM is under way
(NCT01653340) and preliminary results are expected by
the end of 2013. Until proper evidence is provided the
present expert group recommends that spinal cord
stimulation is strictly avoided in patients with primary
headache syndromes.
Conclusion and General Recommendation
The purpose of this position paper, as a result of the
collaboration of an multidisciplinary Expert Group onNeurostimulation of the European Headache Federation,
is to give an assessment and recommendation for the
use of the currently available neuromodulation devices
in headache treatment. This overview is based on the
scientific level obtained through controlled studies, on
existing clinical practice, directly related side effects and
overall safety. Because the available data regarding the
various stimulation approaches are so scarce and vari-
able, this recommendation is also based on the definition
of a clinically significant improvement. In 2008, recom-
mendations put forth by the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) panel and the IHS established a 30% re-
duction in pain as clinically meaningful [31,32]. The au-
thors of this recommendation feel that this minimal
requirement is only sufficient in otherwise medically in-
tractable chronic patients, otherwise a 50% reduction in
pain should be acquired. Prevention of headache days is
certainly the single most clinically relevant item in medical
intractable patients and the most important reason why
these patients seek therapy. However, clinical trial assess-
ments should not be limited to the degree of pain relief or
headache days because this alone may not be necessary for
a clinically meaningful improvement, but should include
tolerability, reductions in headache-related disability, im-
provement in pain-specific quality of life, total costs and
improvement in functional capacity. Unfortunately, re-
garding these outcome parameters even less data exists for
neurostimulation devices in headache treatment.
For all of the above mentioned methods and devices,
the following recommendations are uniquely effective
and have to be seen as the basic qualification and re-
quirement which may be additional to the specific rec-
ommendations for each method as outlines in the
respective chapter.
1) From a medical standpoint, the application of a
neurostimulator, either in a trial or on the basis of a
CE mark treatment, should be considered only once
all alternative drug and behavioural therapies as
recommended by international guidelines have failed
and medication overuse headache is excluded.
2) This involves that the patient is considered chronic,
following the current IHS definition [39] and have
been evaluated at a tertiary care headache center.
3) This involves that the patient is considered medically
intractable as defined by international consensus [10].
4) Non-invasive medical technologies should be
considered prior to implantation of a neurostimulator
and the least invasive and most effective treatment
should always be first line therapy.
Given the heterogeneous data in terms of patient
numbers, inclusion requirements, headache diagnosis,
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lished studies, the authors cannot unequivocally give a
ranking of neurostimulation methods. The global evalu-
ation leads to the following ad interim conclusion:
1) In CCH it is advisable to use SPG [79,80] or ONS
[55,59], before considering DBS. Although the
treatment effects seem clinically equal, the side
effects of the more invasive DBS treatment are
to be considered [43]
2) In CM the use of ONS seems acceptable although
based on limited evidence. Application of the non-
invasive tVNS, tDCS, rTMS, TENS and tSNS in
chronic headaches are not yet evidence based, given
the poor amount of controlled data. However, it needs
to be mentioned that these devices are relatively
harmless when compared to more invasive and costly
neurostimulation devices and may be tried before
using more invasive neurostimulation devices.
The authors note that therapeutic neurostimulation in
headache and pain is a fast evolving field and that no
recommendations can be given using the methodological
arsenal of evidence based medicine. One of the reasons
is the limited use of a proper placebo condition or sham
control and randomized sham and subthreshold stimula-
tion was included only in the SPG study on acute Clus-
ter headache. While sham is in principle available in
central neuromodulation (DBS) [30] it is nearly impos-
sible in peripheral neuromodulation devices, given that
peripheral nerve stimulation is always perceived. However,
we recommend that proper done controlled and random-
ized studies are required before a given neurostimulation
device is implemented and clinically used. A CE-mark is
not equivalent to a randomized study following IHS re-
quirements, as no clinical data supporting the benefit of a
medical device are needed to acquire the CE mark, but
only data showing that the respective device is probably
harmless. The authors suggest the following recommenda-
tions for clinical trial involving neurostimulation devices
in headache treatment:
1) Trials investigating invasive neurostimulator devices
should only involve patients who are considered
chronic, following the current IHS definition [38].
If a given method proved efficacy in the chronic state,
follow-up studies may broaden the indication to
severely disabling episodic states, if medically not
sufficiently treatable.
2) Trials investigating neurostimulator devices should
only involve patients who are not suffering from
medication overuse headache and are considered
medically intractable as defined by international
consensus [10].3) Clinical trial assessments should have the primary
endpoint of the degree of pain relief or reduction in
headache days. Next to adverse events, secondary
endpoints should include reductions in headache-
related disability, improvement in pain-specific
quality of life and improvement in functional
capacity.
In summary, neurostimulation should only be consid-
ered in patients that have tried all first-line therapies
recommended in European guidelines [3], and that both
pain and headache clinicians need to follow international
consensus on that matter [10,17]. The greatest limitation
for clinical use is the lack of proper controlled studies
[159]. Consequently, any devices that have not been in-
vestigated in such controlled studies and have shown to
be effective with an acceptable side effect profile should
not be used at all. The authors note that it is inherent to
neurostimulation devices, perhaps with the only excep-
tion of DBS so far, to lack a proper placebo condition.
Most available trials actually used infrathreshold stimu-
lation intensities as controls, but blinding in patients
perceiving no or few sensations may be difficult to main-
tain. It is crucial to recruit neurostimulation naïve pa-
tients for future trials, but as a recent editorial suggested
this will be an increasing challenge due to the negative
role of the social media (Internet blogs, Facebook etc.)
[160]. International guidelines, preferably agreed be-
tween the IHS and EHF how to conduct such studies are
clearly warranted.
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